{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:49Z","timestamp":1790697889905,"version":"4.1.0"},"reference-count":11,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate tumor control and ocular safety associated with high-dose intravitreal (IVT) topotecan (100 \u00b5g) for isolated recurrent solid retinal tumors in children with retinoblastoma.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This retrospective case series was based on a prospectively maintained clinical database and included 10 eyes of 10 patients with isolated recurrent solid retinal tumors following prior systemic and\/or intra-arterial chemotherapy. All eyes received IVT topotecan (100 \u00b5g\/0.1 mL) using a standardized injection protocol, with adjunctive focal consolidation therapy (laser photocoagulation and\/or cryotherapy) administered as clinically indicated. Primary outcomes included complete tumor regression, globe salvage, ocular toxicity, and metastatic events.\n                    <jats:bold>Results:<\/jats:bold>\n                    The mean interval from the last prior treatment to recurrence was 13 (range, 3\u201324) months. Each eye received a median of 2 injections (range, 1\u20136; mean, 2.7 injections). Complete tumor regression was achieved in all eyes (100%). No clinically appreciable ocular toxicity, systemic toxicity, enucleations, or metastatic events occurred during a mean follow-up of 12 (range, 6\u201324) months.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    High-dose IVT topotecan combined with focal consolidation therapy appears to be a promising treatment option for isolated recurrent solid retinal tumors in retinoblastoma, achieving excellent tumor control with low observed toxicity during the available follow-up period.\n                  <\/jats:p>","DOI":"10.1177\/24741264261460655","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:30:24Z","timestamp":1781764224000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["High-Dose Intravitreal Topotecan Combined With Focal Consolidation Therapy for Recurrent Retinal Tumors in Retinoblastoma"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-2013","authenticated-orcid":false,"given":"Franco","family":"Benvenuto","sequence":"first","affiliation":[{"name":"Ophthalmology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"},{"name":"Unit of Innovative Treatments, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0996-5927","authenticated-orcid":false,"given":"Belen","family":"Cancela","sequence":"additional","affiliation":[{"name":"Unit of Innovative Treatments, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Vater","sequence":"additional","affiliation":[{"name":"Unit of Innovative Treatments, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Decanio","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Freytes","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-0919","authenticated-orcid":false,"given":"Eric","family":"Warriner","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Fandi\u00f1o","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[{"name":"Unit of Innovative Treatments, Hospital de Pediatr\u00eda Prof. Dr. JP Garrahan, Buenos Aires, Argentina"},{"name":"National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-199406000-00014"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2013.06.003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.12.015"},{"issue":"1","key":"e_1_3_2_5_2","first-page":"56","article-title":"Intravitreal chemotherapy for retinoblastoma: rationale and technique","volume":"5","author":"Shields CL","year":"2014","unstructured":"Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Shields JA. Intravitreal chemotherapy for retinoblastoma: rationale and technique. Retina Today. 2014;5(1):56-60.","journal-title":"Retina Today"},{"issue":"7","key":"e_1_3_2_6_2","first-page":"1324","article-title":"Ocular pharmacology of topotecan and its potential use as an intravitreal agent","volume":"33","author":"Schaiquevich P","year":"2013","unstructured":"Schaiquevich P, Buitrago E, Taich P, et al. Ocular pharmacology of topotecan and its potential use as an intravitreal agent. Retina. 2013;33(7):1324-1332.","journal-title":"Retina"},{"issue":"6","key":"e_1_3_2_7_2","first-page":"1045","article-title":"Topotecan toxicity compared with melphalan in intravitreal injections for retinoblastoma","volume":"40","author":"Francis JH","year":"2020","unstructured":"Francis JH, Abramson DH, Ji X, Shields CL, Marr BP. Topotecan toxicity compared with melphalan in intravitreal injections for retinoblastoma. Retina. 2020;40(6):1045-1052.","journal-title":"Retina"},{"key":"e_1_3_2_8_2","first-page":"265","article-title":"Retinal toxicity of topotecan after repeated intravitreal administration in rabbits","volume":"145","author":"Fandi\u00f1o AC","year":"2016","unstructured":"Fandi\u00f1o AC, S\u00e1nchez AV, Del Sole MJ, Giarola LB, Schaiquevich P. Retinal toxicity of topotecan after repeated intravitreal administration in rabbits. Exp Eye Res. 2016;145:265-271.","journal-title":"Exp Eye Res"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109026"},{"issue":"5","key":"e_1_3_2_10_2","first-page":"644","article-title":"High-dose intravitreal topotecan for retinoblastoma","volume":"103","author":"Abramson DH","year":"2019","unstructured":"Abramson DH, Francis JH, Marr BP, Dunkel IJ. High-dose intravitreal topotecan for retinoblastoma. Br J Ophthalmol. 2019;103(5):644-647.","journal-title":"Br J Ophthalmol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004283"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.012"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261460655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261460655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261460655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:52Z","timestamp":1790695552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261460655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":11,"alternative-id":["10.1177\/24741264261460655"],"URL":"https:\/\/doi.org\/10.1177\/24741264261460655","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"24741264261460655"}}